Dr. Andrew Young -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Andrew Young, a Internal Medicine physician based in City, MO. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Andrew Young has received $2,078.14 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Andrew Young
- Medical Specialty: Internal Medicine
- Practice Location: City, MO, Missouri
- NPI Number: 1641699234
- Transparency Score: 50/100
- Payment Records Span: 2025-08-12 to 2025-08-12
Payment Summary
Dr. Andrew Young has received a total of $2,078.14 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $2,078.14 per transaction.
- Total Payments Received: $2,078.14
- Number of Transactions: 1
- Average Payment: $2,078.14
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Internal Medicine. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Andrew Young's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Consulting Fees | $2,078.14 | Advisory board participation, clinical consulting, and expert opinion services |
The largest payment category for Dr. Andrew Young is Consulting Fees, accounting for 100% ($2,078.14) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Andrew Young. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Boehringer Ingelheim | $2,078.14 | 1 |
Dr. Andrew Young has a financial relationship with Boehringer Ingelheim, receiving $2,078.14 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Andrew Young. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Entresto -- Referenced in payment records from pharmaceutical companies to Dr. Andrew Young
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Andrew Young's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Andrew Young has received $2.1K across 1 pharmaceutical payments as a Internal Medicine physician in City, MO. Top paying companies include Boehringer Ingelheim ($2.1K). The physician received a single payment totaling $2,078 in 2025. This payment was categorized as consulting fees. The entire amount came from one company, Boehringer Ingelheim, representing 100% of the total payments received.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Andrew Young is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
Patients may wish to inquire about any potential influence on treatment decisions, though this single payment does not necessarily indicate bias. Always feel free to ask your doctor directly about their pharmaceutical relationships.
Peer Comparison: How Dr. Andrew Young Compares to Other Internal Medicine Physicians
For Internal Medicine physicians, payment profiles vary widely, but a single, substantial payment from one company is less common than more diversified engagements.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Andrew Young in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Boehringer Ingelheim | $2,078.14 | consulting | Entresto | 2025-08-12 | Not Assessed |
Frequently Asked Questions About Dr. Andrew Young's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
How much pharma money has Andrew Young received?
Andrew Young has received a total of $2.1K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.
Is Andrew Young taking too much pharma money?
Andrew Young has received $2.1K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Internal Medicine), the types of payments, and how they compare to peers. The largest payment category is consulting ($2.1K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.
What pharma companies pay Andrew Young?
The top pharmaceutical companies paying Andrew Young are: Boehringer Ingelheim ($2.1K). These payments cover various categories including consulting, meals, speaking fees, and research grants.
What kinds of payments does Andrew Young receive?
Andrew Young's payments by type: consulting: $2.1K. Consulting fees suggest active advisory roles with pharmaceutical companies.
Should I switch doctors because of pharma payments?
Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.
How do Andrew Young's payments compare to other Internal Medicine doctors?
To compare, look at the total amount ($2.1K), number of payments (1), and the types of payments received. Internal Medicine physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.
How can I verify Andrew Young's payment data?
You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1641699234). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.
Do pharma payments affect prescribing quality?
Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.
What stands out about Andrew Young's pharma payment profile?
The physician's payment profile is highly concentrated with a single company and payment type. Andrew Young has received $2.1K in total pharma payments.
How does Andrew Young compare to peers in Internal Medicine?
For Internal Medicine physicians, payment profiles vary widely, but a single, substantial payment from one company is less common than more diversified engagements.
Are Andrew Young's pharma relationships typical for Internal Medicine?
The data indicates a recent engagement, with all recorded activity in 2025.
What should patients of Andrew Young know about these payments?
Patients may wish to inquire about any potential influence on treatment decisions, though this single payment does not necessarily indicate bias.
What patterns are visible in Andrew Young's payment history?
The drug 'Entresto' is associated with the payment, suggesting a potential focus area.
Understanding This Doctor Payment Report
This transparency report for Dr. Andrew Young is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Internal Medicine physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Andrew Young's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Andrew Young and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Internal Medicine Specialty Payment Data -- See payment patterns for all internal medicine physicians
- Missouri Physician Payments -- Browse pharmaceutical payments to physicians in Missouri
- Internal Medicine Physicians in Missouri -- Compare Dr. Andrew Young to peers in the same state and specialty
- Boehringer Ingelheim Payment Profile -- View all payments made by Dr. Andrew Young's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Andrew Young's NPI (1641699234) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.